FDA Approves Zytiga Plus Prednisone for Earlier Form of Metastatic Prostate Cancer
News
Zytiga (abiraterone acetate) is now approved in the U.S. to treat metastatic high-risk castration-sensitive prostate cancer (CSPC) in combination with prednisone, Janssen Pharmaceutical Companies announced. The U.S. Food and Drug ... Read more